on BioNxt Solutions Inc. (CVE:BNXT)
BioNxt Advances Cladribine Sublingual Drug Development for Multiple Sclerosis
BioNxt Solutions Inc. has reported significant progress in its Cladribine sublingual thin-film drug program, aimed at enhancing the treatment of multiple sclerosis (MS). Key milestones include successful technology transfers to a European contract development and manufacturing organization (CDMO) for the production of pharmaceutical-grade sublingual thin films.
The active pharmaceutical ingredient for Cladribine is en route to the CDMO. A pilot batch will be manufactured for upcoming preclinical and clinical phases, including a large-animal study in October to assess bioavailability. This study will inform final dosage optimizations before human trials.
CEO Hugh Rogers emphasized the program's potential to improve patient outcomes and market accessibility through enhanced drug delivery. The first human clinical study is targeted for early 2026, marking a crucial step in BioNxt's development pipeline.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all BioNxt Solutions Inc. news